title: Hypoacetylation, hypomethylation, and dephosphorylation of H2B histones and excessive histone deacetylase activity in DU-145 prostate cancer cells.
abstract: BACKGROUND
  Hypoacetylation on histone H3 of human prostate cancer cells has been described. Little is known about the modifications of other histones from prostate cancer cells.
  
  
  METHODS
  Histones were isolated from the prostate cancer cell line DU-145 and the non-malignant prostatic cell line RC170N/h. Post-translational modifications of histone H2B were determined by liquid chromatography-mass spectrometry (LC-MS)/MS.
  
  
  RESULTS
  The histone H2B of the prostate cancer cell line DU-145 was found to have hypoacetylation, hypomethylation, and dephosphorylation as compared to the non-malignant prostatic cell line RC170N/h. H2B regained acetylation on multiple lysine residues, phosphorylation on Thr19, and methylation on Lys23 and Lys43 in the DU-145 cells after sodium butyrate treatment.
  
  
  CONCLUSIONS
  The histone H2B of DU-145 prostate cancer cells are hypoacetylated, hypomethylated, and dephosphorylated. Histone deacetylase inhibitor reversed this phenotype. Epigenetic agent may therefore be useful for prostate cancer therapy and worth further investigation.
authors.affiliation: Department of Oncology, The People's Hospital of Henan Province, Zhengzhou, Henan, 450052, China.|Department of Medicine, New York Medical College, Valhalla, NY, 10595, USA.
authors.forename: Shundong
authors.initials: S
authors.lastname: Cang
authors.affiliation: Center for Biomedical Mass Spectrometry, Boston University School of Medicine, Boston, MA, 02118, USA.|Present address: Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 10591, USA.
authors.forename: Xiaobin
authors.initials: X
authors.lastname: Xu
authors.affiliation: Department of Oncology, The People's Hospital of Henan Province, Zhengzhou, Henan, 450052, China.|Department of Medicine, New York Medical College, Valhalla, NY, 10595, USA.
authors.forename: Yuehua
authors.initials: Y
authors.lastname: Ma
authors.affiliation: Department of Medicine, New York Medical College, Valhalla, NY, 10595, USA. Delong_liu@nymc.edu.
authors.forename: Delong
authors.initials: D
authors.lastname: Liu
authors.affiliation: Department of Medicine, New York Medical College, Valhalla, NY, 10595, USA. Jen-Wei_Chiao@nymc.edu.
authors.forename: J W
authors.initials: JW
authors.lastname: Chiao
mesh_terms: D000107:Acetylation / Q000187:drug effects; D000595:Amino Acid Sequence; D020148:Butyric Acid / Q000494:pharmacology; D002460:Cell Line; D045744:Cell Line, Tumor; D002853:Chromatography, Liquid; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology; D006655:Histone Deacetylases / Q000378:metabolism*; D006657:Histones / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008239:Lysine / Q000235:genetics / Q000378:metabolism; D008297:Male; D008745:Methylation / Q000187:drug effects; D008969:Molecular Sequence Data; D010766:Phosphorylation / Q000187:drug effects; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology; D011499:Protein Processing, Post-Translational; D053719:Tandem Mass Spectrometry; D013912:Threonine / Q000235:genetics / Q000378:metabolism
chemical_list: D056572:Histone Deacetylase Inhibitors; D006657:Histones; D020148:Butyric Acid; D013912:Threonine; D006655:Histone Deacetylases; D008239:Lysine